- Catheter Precision (VTAK, Financial) reports a 200% increase in LockeT sales for Q2 2025 compared to Q2 2024.
- Major US hospitals to place orders exceeding $100,000 each by the end of 2025.
- LockeT receives CE Mark approval, facilitating distribution expansion in Europe.
Catheter Precision, Inc. (VTAK), a leading US-based medical device company, has announced significant growth in sales of its LockeT device, recording a 200% increase in Q2 2025 compared to the same quarter in 2024. The surge in sales reflects the product's growing acceptance and demand within the healthcare market.
Several prominent US hospitals, including Montefiore in Bronx, NY, Eisenhower Health in Rancho Mirage, CA, and Overland Park Regional Medical Center in Overland Park, KS, are expected to place purchase orders exceeding $100,000 each for LockeT by the end of 2025. This development highlights the device's importance and applicability in critical patient care settings.
Following the recent CE Mark approval for European market entry, Catheter Precision (VTAK, Financial) has successfully enlisted a distributor in Italy and is in the final stages of securing distribution agreements in Spain, Portugal, and the UK. A pivotal live demonstration of LockeT is scheduled for June 16 at an Italian symposium, led by a key opinion leader, which aims to boost product awareness across the new European markets.
The LockeT device, designed for suture retention and aiding in wound closure post-percutaneous venous punctures, is positioned as a Class 1 FDA-registered product. The company's CEO, David Jenkins, expressed excitement over the expanding use and forthcoming sales activities, emphasizing a strategic focus on increasing product usage and enhancing market presence across Europe.
